Analyst Cory Kasimov works at JPMORGAN and is focused on the Healthcare sector with 337 price targets and ratings documented since 2012 spanning on 22 stocks. Analyst's average stock valuation to be materialised ratio is 69.19% with an average time for price targets to be met of 266.82 days.
Most recent stock forecast was given on NVCR, NovoCure Limited at 17-Mar-2023.
Cory Kasimov best performing recommendations are on EDIT (EDITAS MEDICINE, INC).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY, INC) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
28
$9.5 (51.35%)
25
9 days ago
3/9 (33.33%)
$10.29 (42.30%)
168
Buy
33
$14.5 (78.38%)
26
9 days ago
25/36 (69.44%)
$11.75 (41.85%)
593
Hold
20
$1.5 (8.11%)
19
9 days ago
10/21 (47.62%)
$6.16 (21.85%)
34
Buy
26
$7.5 (40.54%)
20
9 days ago
10/16 (62.5%)
$7.71 (27.86%)
93
Buy
27
$8.5 (45.95%)
27
9 days ago
2/16 (12.5%)
$9.79 (42.07%)
71
